|
 Shares rose as much as 10 percent in early trading in Paris and were
up 6.1 percent at 37 euros at 1034 GMT.
Carmat said on Monday the implantation of its bioprosthetic
artificial heart was carried out with the approval of the French
national agency for safety of medicines and health products and the
country's patient protection committee.
It added that it would not publish "specific information concerning
the implantations of each patient involved in the study or their
condition."
The company, whose first shareholders included planemaker Airbus and
private equity fund Truffle Capital, has not generated any
significant revenue but is closely followed by investors as heart
diseases represent a leading cause of death worldwide and its
devices could represent a major medical breakthrough if proven
reliable.
Carmat's shares have lost 9.8 percent so far this year, valuing the
company at about 207 million euros ($230 million). It reported a net
loss of 17.5 million euros in 2015.
[to top of second column] |
(Reporting by Mathieu Rosemain; Editing by Mark Potter)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|
